Medivir Strengthens its Management Team

01-Sep-2011 - Sweden

Medivir AB announced several new appointments to its executive management team.

Dr Maris Hartmanis has been appointed to Medivir’s management team as deputy CEO and COO (Chief Operating Officer). In parallel to this appointment Maris Hartmanis will continue to work as CEO of Biophausia, the specialty pharmaceutical company which recently was acquired by Medivir. Maris Hartmanis has extensive experience of the pharmaceutical industry, most notably holding senior positions at Gambro, Amersham and Pharmacia.

Professor Bertil Samuelsson has been appointed CSA (Chief Scientific Advisor). Bertil Samuelsson previously held the position of CSO (Chief Scientific Officer) and will leave the operational management team to focus his efforts on the strategic development of Medivir’s R&D, including new project opportunities.

Medivir also names Dr Charlotte Edenius as Executive VP Research & Development. In her new role she will assume the operational responsibilities for Medivir’s Research and Development. Charlotte Edenius currently holds the position as VP Research & Development projects at Medivir.

In order to strengthen Medivir’s capabilities in clinical development Dr Jens D. Kristensen has been recruited as Executive VP Clinical to head the clinical unit at Medivir. Prior to joining Medivir Jens Kristensen most recently served as Vice President Clinical Development at Karo Bio and also has experience working at AstraZeneca within clinical development.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances